NASDAQ:MACK - Merrimack Pharmaceuticals News Headlines

$5.75
+0.08 (+1.41 %)
(As of 06/24/2019 10:05 AM ET)
Today's Range
$5.5301
Now: $5.75
$5.75
50-Day Range
$5.52
MA: $5.90
$6.25
52-Week Range
$3.34
Now: $5.75
$9.52
Volume1,682 shs
Average Volume59,110 shs
Market Capitalization$76.71 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28

Headlines

Merrimack Pharmaceuticals (NASDAQ MACK) News Headlines

Source:
DateHeadline
The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech OfferingThe Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
www.benzinga.com - May 31 at 8:23 AM
Merrimack axes remaining staff, execs after selling assets to New York startupMerrimack axes remaining staff, execs after selling assets to New York startup
www.bizjournals.com - May 31 at 8:23 AM
Merrimack -2.6% as it decides against saleMerrimack -2.6% as it decides against sale
seekingalpha.com - May 30 at 6:42 PM
Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash DividendMerrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
finance.yahoo.com - May 30 at 6:42 PM
Merrimack Reports First Quarter 2019 Financial ResultsMerrimack Reports First Quarter 2019 Financial Results
www.prnewswire.com - May 10 at 7:59 AM
COMM 2014-UBS2 Mortgage Trust -- Moodys affirms ten classes of COMM 2014-UBS2COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2
finance.yahoo.com - May 3 at 7:14 PM
Merrimack to cut headcount after MM-310 flopMerrimack to cut headcount after MM-310 flop
seekingalpha.com - April 30 at 6:52 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACKSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
finance.yahoo.com - April 9 at 10:15 PM
Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces InvestigationMerrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
finance.yahoo.com - April 8 at 7:50 PM
Merrimack Discontinues Cancer Study Amidst LayoffsMerrimack Discontinues Cancer Study Amidst Layoffs
247wallst.com - April 5 at 7:49 PM
TrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losersTrovaGene leads healthcare gainers; Merrimack Pharmaceuticals and Syros Pharmaceuticals among losers
seekingalpha.com - April 5 at 12:25 PM
The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather UpsetThe Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
finance.yahoo.com - April 5 at 10:42 AM
Merrimack bails on lead candidate; shares down 9% after hoursMerrimack bails on lead candidate; shares down 9% after hours
seekingalpha.com - April 4 at 8:04 PM
Merrimack Discontinues Development of MM-310Merrimack Discontinues Development of MM-310
finance.yahoo.com - April 4 at 8:04 PM
Merrimack shelves another cancer drug, plans more layoffsMerrimack shelves another cancer drug, plans more layoffs
finance.yahoo.com - April 4 at 8:04 PM
Merrimack Pharmaceuticals, Inc. Estimate MomentumMerrimack Pharmaceuticals, Inc. Estimate Momentum
www.nasdaq.com - March 20 at 10:47 PM
Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results - PRNewswireMerrimack Reports Fourth Quarter and Full Year 2018 Financial Results - PRNewswire
www.prnewswire.com - March 7 at 8:33 AM
Merrimack Reports Fourth Quarter and Full Year 2018 Financial ResultsMerrimack Reports Fourth Quarter and Full Year 2018 Financial Results
finance.yahoo.com - March 6 at 8:27 AM
John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman - NasdaqJohn M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman - Nasdaq
www.nasdaq.com - December 10 at 5:29 PM
John M. Dineen Appointed to Syneos Health Board of Directors, Named ChairmanJohn M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman
finance.yahoo.com - December 10 at 5:29 PM
Merrimack (MACK) Down 7.5% Since Last Earnings Report: Can It Rebound?Merrimack (MACK) Down 7.5% Since Last Earnings Report: Can It Rebound?
www.zacks.com - December 7 at 5:41 PM
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3
finance.yahoo.com - November 9 at 5:35 PM
Merrimack to shelve lead cancer drug, lay off most of workforceMerrimack to shelve lead cancer drug, lay off most of workforce
finance.yahoo.com - November 8 at 5:38 PM
Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMTEdited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT
finance.yahoo.com - November 8 at 8:21 AM
Merrimack Pharmaceuticals (MACK) CEO Richard Peters on Q3 2018 Results - Earnings Call TranscriptMerrimack Pharmaceuticals (MACK) CEO Richard Peters on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 5:47 PM
Merrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio ReviewMerrimack Reports Third Quarter 2018 Financial Results and Provides Strategic Update Following Portfolio Review
finance.yahoo.com - November 7 at 8:19 AM
Merrimack Pharmaceuticals Q3 Earnings PreviewMerrimack Pharmaceuticals Q3 Earnings Preview
finance.yahoo.com - November 6 at 5:33 PM
Merrimack Announces Timing of Third Quarter 2018 Investor Conference CallMerrimack Announces Timing of Third Quarter 2018 Investor Conference Call
finance.yahoo.com - October 31 at 5:29 PM
Biotech Stock Roundup: BIIB Tops, MACK Plunges, REGNs Asthma Drug Gets FDA NodBiotech Stock Roundup: BIIB Tops, MACK Plunges, REGN's Asthma Drug Gets FDA Nod
www.zacks.com - October 24 at 5:07 PM
Merrimack Fails Mid-Stage Study, But 2 Shots On Goal May Help It Redeem ItselfMerrimack Fails Mid-Stage Study, But 2 Shots On Goal May Help It Redeem Itself
seekingalpha.com - October 22 at 5:21 PM
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to FutilityMerrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to Futility
www.marketwatch.com - October 20 at 8:19 AM
Merrimack Pharmaceuticals (MACK) PT Lowered to $4 at Baird as MM-121 DisappointsMerrimack Pharmaceuticals (MACK) PT Lowered to $4 at Baird as MM-121 Disappoints
www.streetinsider.com - October 20 at 8:19 AM
Merrimack discontinues Phase 2 study of MM-121 in patients with NSCLC due to futilityMerrimack discontinues Phase 2 study of MM-121 in patients with NSCLC due to futility
seekingalpha.com - October 20 at 8:19 AM
Why Merrimack Pharma Is Terminating Its Midstage Lung Cancer StudyWhy Merrimack Pharma Is Terminating Its Midstage Lung Cancer Study
247wallst.com - October 20 at 8:19 AM
US STOCKS ON THE MOVE-AmEx, AIG, P&G, PayPal, Skechers, Apple, TeslaUS STOCKS ON THE MOVE-AmEx, AIG, P&G, PayPal, Skechers, Apple, Tesla
www.nasdaq.com - October 19 at 5:10 PM
Mid-Morning Market Update: Markets Open Higher; Procter & Gamble Profit Tops EstimatesMid-Morning Market Update: Markets Open Higher; Procter & Gamble Profit Tops Estimates
www.nasdaq.com - October 19 at 5:10 PM
Merrimacks String of Failures Continues With Lung Cancer Study Shelved After Midstage TrialsMerrimack's String of Failures Continues With Lung Cancer Study Shelved After Midstage Trials
feeds.benzinga.com - October 19 at 12:16 PM
Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to ...Merrimack Discontinues Phase 2 SHERLOC Study of MM-121 in Patients with Non-Small Cell Lung Cancer Due to ...
www.prnewswire.com - October 19 at 8:25 AM
Merrimack Pharmaceuticals stock plummets toward record low after cancer drug trial terminatedMerrimack Pharmaceuticals' stock plummets toward record low after cancer drug trial terminated
www.marketwatch.com - October 19 at 8:25 AM
Detailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Clearside Biomedical, JELD-WEN Holding, L.B. Foster, Merrimack Pharmaceuticals, Everi, and Drive Shack — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - October 16 at 8:24 AM
Merrimack (MACK) Focuses on Early Stage Pipeline and Cost CutsMerrimack (MACK) Focuses on Early Stage Pipeline and Cost Cuts
www.zacks.com - October 11 at 4:51 PM
Global Next-Generation Antibody Therapies Market Forecast 2018-2028 - Visiongain ReportGlobal Next-Generation Antibody Therapies Market Forecast 2018-2028 - Visiongain Report
www.prnewswire.com - October 2 at 4:51 PM
Merrimack Pharma (MACK) Receives $5M Milestone Payment from ShireMerrimack Pharma (MACK) Receives $5M Milestone Payment from Shire
www.streetinsider.com - September 20 at 4:55 PM
Merrimack receives $5M milestone payment from ShireMerrimack receives $5M milestone payment from Shire
seekingalpha.com - September 20 at 4:55 PM
Merrimack Receives $5 Million Milestone Payment from ShireMerrimack Receives $5 Million Milestone Payment from Shire
finance.yahoo.com - September 20 at 8:21 AM
Merrimack Pharmaceuticals (MACK) Presents at Bairds Global Healthcare Conference - SlideshowMerrimack Pharmaceuticals (MACK) Presents at Baird's Global Healthcare Conference - Slideshow
seekingalpha.com - September 7 at 5:06 PM
Merrimack Pharma completes enrollment in mid-stage study of MM-121 in certain type of lung cancer; shares down 2%Merrimack Pharma completes enrollment in mid-stage study of MM-121 in certain type of lung cancer; shares down 2%
seekingalpha.com - September 6 at 5:03 PM
Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?Merrimack (MACK) Up 6.7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - September 6 at 5:03 PM
Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)Merrimack Completes Enrollment in Randomized Phase 2 SHERLOC Study of MM-121 (seribantumab) in Non-Small Cell Lung Cancer (NSCLC)
finance.yahoo.com - September 6 at 8:25 AM
Edited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMTEdited Transcript of MACK earnings conference call or presentation 7-Aug-18 12:30pm GMT
finance.yahoo.com - August 16 at 5:29 PM
This page was last updated on 6/24/2019 by MarketBeat.com Staff

Featured Article: Stock Symbol

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel